Apollon Wealth Management’s Quoin Pharmaceuticals QNRX Stock Holding History

Apollon Wealth Management’s Portfolio QNRX Stock Details QNRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-2,286	Closed	-$17.9K	–	1312
2025 Q1	$17.9K	Hold	2,286	–	–	﹤0.01%	1197
2024 Q4	$52.1K	Buy	+2,286	New	+$52.5K	﹤0.01%	1167

Other funds holding QNRX

RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return

GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

SBI Securities Tokyo, Japan $3.65B AUM 41.88% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Apollon Wealth Management's QNRX Position: Q2 2025 in Review

Apollon Wealth Management sold out of Quoin Pharmaceuticals (QNRX) in Q2 2025, closing a stake of 2,286 shares — an estimated $17.9K sold.

Apollon Wealth Management first reported a position in QNRX in Q4 2024 and held it in 2 quarters. The position peaked at $52.1K in Q4 2024. 7 funds tracked by Wall St. Rank hold QNRX as of Q2 2025.

Apollon Wealth Management reported no remaining Quoin Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
Apollon Wealth Management sold 2,286 Quoin Pharmaceuticals shares in Q2 2025, an estimated $17.9K.
Apollon Wealth Management first reported a position in Quoin Pharmaceuticals in Q4 2024 and held it in 2 quarters.
Apollon Wealth Management's Quoin Pharmaceuticals position peaked at $52.1K in Q4 2024.
7 funds tracked by Wall St. Rank held Quoin Pharmaceuticals as of Q2 2025.

Based on Apollon Wealth Management's 13F filing for Q2 2025, filed 25 Jul 2025.